BEQGX | VITSX | BEQGX / VITSX | |
Total Expense Ratio | 0.66 | 0.03 | 2,200% |
Annual Report Gross Expense Ratio | 0.66 | 0.03 | 2,200% |
Fund Existence | 34 years | 28 years | - |
Gain YTD | 11.849 | 12.267 | 97% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 5000000 | 0% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 1.8B | 1.95T | 0% |
Annual Yield % from dividends | 0.62 | 1.17 | 53% |
Returns for 1 year | 15.82 | 14.92 | 106% |
Returns for 3 years | 68.18 | 79.19 | 86% |
Returns for 5 years | 22.69 | 95.37 | 24% |
Returns for 10 years | 51.62 | 248.55 | 21% |
1 Day | |||
---|---|---|---|
STOCK / NAME | Price $ | Chg $ | Chg % |
FULC | 8.84 | 0.34 | +4.00% |
Fulcrum Therapeutics | |||
PAC | 248.56 | 1.05 | +0.42% |
Grupo Aeroportuario del Pacifico SAB de CV Amer Dep Shares (each rep 10 Ser B shares) | |||
ETNB | 14.70 | N/A | N/A |
89bio | |||
KAVL | 0.46 | -0.01 | -2.61% |
Kaival Brands Innovations Group | |||
CNTB | 1.58 | -0.11 | -6.51% |
Connect Biopharma Holdings Limited |